{"id":7105,"date":"2026-04-29T04:15:06","date_gmt":"2026-04-28T20:15:06","guid":{"rendered":"https:\/\/moresourcing.com\/u-s-medical-centers-need-a-new-model-for-drug-discovery-and-development\/"},"modified":"2026-04-29T04:15:06","modified_gmt":"2026-04-28T20:15:06","slug":"u-s-medical-centers-need-a-new-model-for-drug-discovery-and-development","status":"publish","type":"post","link":"https:\/\/moresourcing.com\/en\/u-s-medical-centers-need-a-new-model-for-drug-discovery-and-development\/","title":{"rendered":"U.S. Medical Centers Need a New Model for Drug Discovery and Development"},"content":{"rendered":"

<\/p>\n

\n

For more than 50 years, U.S. academic medical centers (AMCs) have been the global engine for pharmaceutical innovation. These university-affiliated hospitals are dedicated to fulfilling the mission areas of medical education, scientific research, and patient care. They have developed a distinctive innovation model in which patient care inspires research questions, public investment supports discovery, and public-private partnerships enable the translation of these breakthroughs into clinical practice. But U.S. AMCs are now facing a major challenge from China, which has emerged as a major rival in the last decade. Its pharmaceuticals R&D sector is on track to become the global industry leader, displacing its U.S. counterpart.<\/p>\n<\/div>\n